Medicare And Alzheimer's Drugs: Grassroots Campaign Opposing Coverage Aims To ‘Take On Big Pharma’
Executive Summary
Nearly 5,000 comments from individuals on CMS’ proposal to restrict coverage of Alzheimer’s drugs argue that Aduhelm should never have been approved and should not be covered. The outpouring is surprising in light of expectations there would be a flood of patient comments urging broader coverage.
You may also be interested in...
Eisai Gives Full Aduhelm Responsibility To Biogen Under Amended Agreement
The companies amended the terms of their Alzheimer’s collaboration to give Biogen full decision-making control over Aduhelm immediately. Eisai’s 50% share of profits and losses from the drug switches to a 2% royalty in 2023. The partners’ agreement for Eisai-led lecanemab remains intact.
A New Patient Voice In The Medicare/Alzheimer’s Drug Coverage Debate
Individuals with Down syndrome are particularly vulnerable to the disease yet would be excluded from participating in clinical trials described in the draft Medicare coverage policy for Alzheimer’s drugs.
A New Patient Voice In The Medicare/Alzheimer’s Drug Coverage Debate
Individuals with Down syndrome are particularly vulnerable to the disease yet would be excluded from participating in clinical trials described in the draft Medicare coverage policy for Alzheimer’s drugs.